Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.21
(2.56%)
CNY 3.21
(2.56%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.93 Billion CNY | -7.72% |
| 2022 | 4.26 Billion CNY | -14.33% |
| 2021 | 4.97 Billion CNY | -1.74% |
| 2020 | 5.06 Billion CNY | 7.23% |
| 2019 | 4.72 Billion CNY | 14.99% |
| 2018 | 4.1 Billion CNY | -4.78% |
| 2017 | 4.31 Billion CNY | 6.21% |
| 2016 | 4.05 Billion CNY | 37.18% |
| 2015 | 2.95 Billion CNY | 25.54% |
| 2014 | 2.35 Billion CNY | 16.7% |
| 2013 | 2.01 Billion CNY | 32.54% |
| 2012 | 1.52 Billion CNY | 14.68% |
| 2011 | 1.32 Billion CNY | 171.87% |
| 2010 | 488.62 Million CNY | 21.23% |
| 2009 | 403.04 Million CNY | 26.71% |
| 2008 | 318.09 Million CNY | 50.97% |
| 2007 | 210.69 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.9 Billion CNY | -0.03% |
| 2024 Q1 | 3.9 Billion CNY | -0.72% |
| 2024 Q3 | 3.91 Billion CNY | 0.31% |
| 2023 Q3 | 4.17 Billion CNY | -0.6% |
| 2023 Q2 | 4.2 Billion CNY | 0.4% |
| 2023 Q1 | 4.18 Billion CNY | -1.74% |
| 2023 Q4 | 3.93 Billion CNY | -5.88% |
| 2023 FY | 3.93 Billion CNY | -7.72% |
| 2022 FY | 4.26 Billion CNY | -14.33% |
| 2022 Q3 | 4.7 Billion CNY | -2.02% |
| 2022 Q4 | 4.26 Billion CNY | -9.48% |
| 2022 Q1 | 4.87 Billion CNY | -2.0% |
| 2022 Q2 | 4.8 Billion CNY | -1.44% |
| 2021 Q4 | 4.97 Billion CNY | -3.54% |
| 2021 FY | 4.97 Billion CNY | -1.74% |
| 2021 Q1 | 5.16 Billion CNY | 1.98% |
| 2021 Q2 | 5.07 Billion CNY | -1.69% |
| 2021 Q3 | 5.15 Billion CNY | 1.61% |
| 2020 Q4 | 5.06 Billion CNY | -2.45% |
| 2020 Q2 | 4.97 Billion CNY | 4.72% |
| 2020 Q1 | 4.74 Billion CNY | 0.6% |
| 2020 FY | 5.06 Billion CNY | 7.23% |
| 2020 Q3 | 5.18 Billion CNY | 4.34% |
| 2019 Q3 | 4.75 Billion CNY | -1.55% |
| 2019 Q2 | 4.82 Billion CNY | 0.76% |
| 2019 FY | 4.72 Billion CNY | 14.99% |
| 2019 Q4 | 4.72 Billion CNY | -0.65% |
| 2019 Q1 | 4.78 Billion CNY | 16.69% |
| 2018 FY | 4.1 Billion CNY | -4.78% |
| 2018 Q1 | 4.19 Billion CNY | -2.65% |
| 2018 Q2 | 4.08 Billion CNY | -2.62% |
| 2018 Q3 | 4.18 Billion CNY | 2.43% |
| 2018 Q4 | 4.1 Billion CNY | -1.93% |
| 2017 Q1 | 4.18 Billion CNY | 3.12% |
| 2017 Q4 | 4.31 Billion CNY | 8.55% |
| 2017 Q3 | 3.97 Billion CNY | -1.83% |
| 2017 Q2 | 4.04 Billion CNY | -3.35% |
| 2017 FY | 4.31 Billion CNY | 6.21% |
| 2016 Q2 | 3.15 Billion CNY | 0.53% |
| 2016 Q1 | 3.14 Billion CNY | 6.21% |
| 2016 FY | 4.05 Billion CNY | 37.18% |
| 2016 Q4 | 4.05 Billion CNY | 20.32% |
| 2016 Q3 | 3.37 Billion CNY | 6.79% |
| 2015 Q1 | 2.67 Billion CNY | 13.61% |
| 2015 FY | 2.95 Billion CNY | 25.54% |
| 2015 Q4 | 2.95 Billion CNY | 4.35% |
| 2015 Q3 | 2.83 Billion CNY | -1.19% |
| 2015 Q2 | 2.86 Billion CNY | 7.18% |
| 2014 Q1 | 2.13 Billion CNY | 5.68% |
| 2014 FY | 2.35 Billion CNY | 16.7% |
| 2014 Q4 | 2.35 Billion CNY | 8.31% |
| 2014 Q3 | 2.17 Billion CNY | -0.48% |
| 2014 Q2 | 2.18 Billion CNY | 2.45% |
| 2013 Q4 | 2.01 Billion CNY | 19.81% |
| 2013 FY | 2.01 Billion CNY | 32.54% |
| 2013 Q2 | 1.62 Billion CNY | 4.91% |
| 2013 Q3 | 1.68 Billion CNY | 3.52% |
| 2013 Q1 | 1.55 Billion CNY | 1.86% |
| 2012 FY | 1.52 Billion CNY | 14.68% |
| 2012 Q1 | 1.35 Billion CNY | 1.71% |
| 2012 Q2 | 1.41 Billion CNY | 4.82% |
| 2012 Q3 | 1.46 Billion CNY | 3.12% |
| 2012 Q4 | 1.52 Billion CNY | 4.32% |
| 2011 Q2 | 1.3 Billion CNY | -5.26% |
| 2011 Q3 | 1.32 Billion CNY | 1.55% |
| 2011 FY | 1.32 Billion CNY | 171.87% |
| 2011 Q4 | 1.32 Billion CNY | 0.36% |
| 2011 Q1 | 1.37 Billion CNY | 181.57% |
| 2010 Q2 | 457.63 Million CNY | 0.0% |
| 2010 FY | 488.62 Million CNY | 21.23% |
| 2010 Q4 | 488.62 Million CNY | 0.0% |
| 2009 FY | 403.04 Million CNY | 26.71% |
| 2008 FY | 318.09 Million CNY | 50.97% |
| 2007 FY | 210.69 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 48.26 Billion CNY | 91.853% |
| Realcan Pharmaceutical Group Co., Ltd. | 16.7 Billion CNY | 76.47% |